Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: A methodological study

Therapeutic Drug Monitoring

Volumn 33, Issue 1, 2011, Pages 94-98

  Paniccia, Rita ^a,b   Antonucci, Emilia ^a   Maggini, Niccolò ^a   Miranda, Marco ^a   Romano, Eloisa ^a   Gori, Anna Maria ^a,b   Marcucci, Rossella ^a,b   Prisco, Domenico ^a,b   Abbate, Rosanna ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda Ospedaliero Universitaria Careggi ^*  (Italy)

Author keywords

clopidogrel; platelet aggregation; platelet function testing; response variability; standardization of methodology

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR;

ANALYTIC METHOD; ANTICOAGULANT THERAPY; ARTICLE; BIOASSAY; BLOOD CLOTTING PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG MONITORING; HIGH RISK PATIENT; HUMAN; INSTRUMENTATION; LIGHT TRANSMITTANCE AGGREGOMETRY; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; RESIDUAL PLATELET REACTIVITY; STANDARDIZATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ANGIOPLASTY; CORONARY ARTERY DISEASE; DRUG MONITORING; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; POINT-OF-CARE SYSTEMS; TICLOPIDINE;

EID: 78751649249     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182052ff4     Document Type: Article

References (39)

1. Mehta SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
2. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
3. Buonamici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity following clopidogrel administration on drug-eluting. J Am Coll Cardiol. 2007;49:2312-2317.
4. Marcucci R, Gori AM, Paniccia R, et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis. 2007;195:e217-e223.
5. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119:237-242.
6. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154:221-231.
7. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849-856.
8. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-933.
9. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45:1157-1164.
10. Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost. 2009;102:7-14.
11. Bonellopalot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2009; 104:1511-1515.
12. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G.A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925-1934.
13. Giusti B, Gori AM, Marcucci R, et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007;17:1057-1064.
14. Giusti B, Gori AM, Marcucci R, et al. Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. Expert Opin Drug Metab Toxicol. 2010;6:393-407.
15. Hochholzer W, Trenk D, Fromm MF, et al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol. 2010;55:2427-2434.
16. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003;107:32-37.
17. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J. 2008;72:1165-1169.
18. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. 2004;109: 3171-3175.
19. Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost. 2007;97:282-287.
20. Harrison P, Keeling D. Platelet hyperactivity and risk of recurrent thrombosis. J Thromb Haemost. 2006;4:2544-2546.
21. Gurbel PA, Becker RC, Mann KG, et al. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007;50: 1822-18234.
22. Michelson AD. Methods for the measurement of platelet function. Am J Cardiol. 2009;103:A20-A26.
23. Cattaneo M, Hayward CPM, Moffat KA, et al. Results of a Worldwide Survey on the Assessment of Platelet Function by Light Transmission Aggregometry Scientific and Standardization Committee Communications: on behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1029.
24. Clinical and Laboratory standards Institute (CLSI). Platelet Function Testing by Aggregometry: Approved Guideline. CLSI document H58-A (ISBN 1-56238-683-2). Wayne, PA: Clinical and Laboratory Standards Institute 2008. Available at: www.clsi.org.
25. Moffat KA, Ledford-Kraemer MR, Nichols WL, et al. Variability in clinical laboratory practice in testing for disorders of platelet function. Results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb Haemost. 2005;93:549-553.
26. Gurbel PA, Bliden KP, Etherington A, et al. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. Thromb Res. 2007;121:107-115.
27. Harrison P, Frelinger AL 3rd, Furman MI, et al. Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007;120:323-336.
28. van Werkum JW, Kleibeuker M, Mieremet N, et al. Evaluation of the platelet response to clopidogrel with light transmittance aggregometry: peak aggregation or late aggregation? J Thromb Haemost. 2007;5: 884-886.
29. Breddin HK. Can platelet aggregometry be standardized? Platelets. 2005; 16:151-158.
30. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927-929.
31. Paniccia R, Antonucci E, Gori AM, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost. 2007;5:1839-1847.
32. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999; 99:620-625.
33. Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol. 2005;3:1392-1396.
34. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost. 2007;98:838-843.
35. Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol. 2009;104:227-233.
36. Paniccia R, Antonucci E, Maggini N, et al. Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. Am J Clin Pathol. 2009;131:834-842.
37. Paniccia R, Antonucci E, Maggini N, et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost. 2010;104: 287-292.
38. Lordkipanidzé M, Pharand C, Palisaitis DA, et al. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel. Thromb Res. 2009;124:546-553.
39. Valgimigli M, Campo G, de Cesare N, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention. Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation. 2009;119:3215-3222.